DXCM Dexcom Stock Outlook 2026: CGM Leader After the Crash — Is the Story Intact?
Dexcom (DXCM) stock analysis 2026: $4.82B TTM revenue up 16.2%, EPS +75.5% to $2.34, P/E 30.8x, GLP-1 drug interaction with CGM adoption, Stelo OTC launch, FreeStyle Libre competition, and analyst consensus Strong Buy with $81.64 target.
DXCM Dexcom CGM